Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients

NCT02132000 is registered in ClinicalTrials.gov with Fengxi Su as lead sponsor.

NCT NCT02132000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02132000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients
Lead sponsor
Fengxi Su
Phase
Phase 2/3
Overall status
Unknown status
Start date
April 30, 2014
Completion date
May 31, 2020
Enrollment
3,036 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer patients in premenopausal, estrogen and/or progesterone receptor positive